Aclipse Therapeutics is an innovative biopharmaceutical company developing life-changing treatments for patients with severe diseases. The company’s current pipeline includes M107, a potential disease-modifying drug for the treatment of gastroparesis proceeding to Phase 2 development, and M102, a dual Nrf2/HSF1 activator for the treatment of ALS and other neurodegenerative diseases proceeding to Phase 1 development. M102 uses a precision medicine approach to identify those ALS patients who are most likely to benefit from the drug. Aclipse has an experienced drug development team and clinical advisory boards of key opinion leaders in gastroparesis and ALS.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.